269 related articles for article (PubMed ID: 22885522)
1. The development and application of small molecule modulators of SF3b as therapeutic agents for cancer.
Webb TR; Joyner AS; Potter PM
Drug Discov Today; 2013 Jan; 18(1-2):43-9. PubMed ID: 22885522
[TBL] [Abstract][Full Text] [Related]
2. The spliceosome as a target of novel antitumour drugs.
Bonnal S; Vigevani L; Valcárcel J
Nat Rev Drug Discov; 2012 Nov; 11(11):847-59. PubMed ID: 23123942
[TBL] [Abstract][Full Text] [Related]
3. SF3B1 mutations constitute a novel therapeutic target in breast cancer.
Maguire SL; Leonidou A; Wai P; Marchiò C; Ng CK; Sapino A; Salomon AV; Reis-Filho JS; Weigelt B; Natrajan RC
J Pathol; 2015 Mar; 235(4):571-80. PubMed ID: 25424858
[TBL] [Abstract][Full Text] [Related]
4. Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors.
Scott LM; Rebel VI
J Natl Cancer Inst; 2013 Oct; 105(20):1540-9. PubMed ID: 24052622
[TBL] [Abstract][Full Text] [Related]
5. Spliceosome mutations in hematopoietic malignancies.
Hahn CN; Scott HS
Nat Genet; 2011 Dec; 44(1):9-10. PubMed ID: 22200771
[TBL] [Abstract][Full Text] [Related]
6. A Comprehensive Overview of Structure-Activity Relationships of Small-Molecule Splicing Modulators Targeting SF3B1 as Anticancer Agents.
Zhang D; Meng F
ChemMedChem; 2020 Nov; 15(22):2098-2120. PubMed ID: 33037739
[TBL] [Abstract][Full Text] [Related]
7. Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A.
Corrionero A; Miñana B; Valcárcel J
Genes Dev; 2011 Mar; 25(5):445-59. PubMed ID: 21363963
[TBL] [Abstract][Full Text] [Related]
8. The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region.
Folco EG; Coil KE; Reed R
Genes Dev; 2011 Mar; 25(5):440-4. PubMed ID: 21363962
[TBL] [Abstract][Full Text] [Related]
9. CRISPR editing of sftb-1/SF3B1 in Caenorhabditis elegans allows the identification of synthetic interactions with cancer-related mutations and the chemical inhibition of splicing.
Serrat X; Kukhtar D; Cornes E; Esteve-Codina A; Benlloch H; Cecere G; Cerón J
PLoS Genet; 2019 Oct; 15(10):e1008464. PubMed ID: 31634348
[TBL] [Abstract][Full Text] [Related]
10. Jerantinine A induces tumor-specific cell death through modulation of splicing factor 3b subunit 1 (SF3B1).
Chung FF; Tan PF; Raja VJ; Tan BS; Lim KH; Kam TS; Hii LW; Tan SH; See SJ; Tan YF; Wong LZ; Yam WK; Mai CW; Bradshaw TD; Leong CO
Sci Rep; 2017 Feb; 7():42504. PubMed ID: 28198434
[TBL] [Abstract][Full Text] [Related]
11. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.
Kaida D; Motoyoshi H; Tashiro E; Nojima T; Hagiwara M; Ishigami K; Watanabe H; Kitahara T; Yoshida T; Nakajima H; Tani T; Horinouchi S; Yoshida M
Nat Chem Biol; 2007 Sep; 3(9):576-83. PubMed ID: 17643111
[TBL] [Abstract][Full Text] [Related]
12. Structures of SF3b1 reveal a dynamic Achilles heel of spliceosome assembly: Implications for cancer-associated abnormalities and drug discovery.
Maji D; Grossfield A; Kielkopf CL
Biochim Biophys Acta Gene Regul Mech; 2019; 1862(11-12):194440. PubMed ID: 31707043
[TBL] [Abstract][Full Text] [Related]
13. Structural Basis of Splicing Modulation by Antitumor Macrolide Compounds.
Cretu C; Agrawal AA; Cook A; Will CL; Fekkes P; Smith PG; Lührmann R; Larsen N; Buonamici S; Pena V
Mol Cell; 2018 Apr; 70(2):265-273.e8. PubMed ID: 29656923
[TBL] [Abstract][Full Text] [Related]
14. Generation of a monoclonal antibody against the mouse Sf3b1 (SAP155) gene product for U2 snRNP component of spliceosome.
Horie A; Isono K; Koseki H
Hybrid Hybridomics; 2003 Apr; 22(2):117-9. PubMed ID: 12831537
[TBL] [Abstract][Full Text] [Related]
15. The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of action.
Finci LI; Zhang X; Huang X; Zhou Q; Tsai J; Teng T; Agrawal A; Chan B; Irwin S; Karr C; Cook A; Zhu P; Reynolds D; Smith PG; Fekkes P; Buonamici S; Larsen NA
Genes Dev; 2018 Feb; 32(3-4):309-320. PubMed ID: 29491137
[TBL] [Abstract][Full Text] [Related]
16. Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B.
Kashyap MK; Kumar D; Villa R; La Clair JJ; Benner C; Sasik R; Jones H; Ghia EM; Rassenti LZ; Kipps TJ; Burkart MD; Castro JE
Haematologica; 2015 Jul; 100(7):945-54. PubMed ID: 25862704
[TBL] [Abstract][Full Text] [Related]
17. Molecular cloning, genetic mapping, and expression of the mouse Sf3b1 (SAP155) gene for the U2 snRNP component of spliceosome.
Isono K; Abe K; Tomaru Y; Okazaki Y; Hayashizaki Y; Koseki H
Mamm Genome; 2001 Mar; 12(3):192-8. PubMed ID: 11252167
[TBL] [Abstract][Full Text] [Related]
18. Combined biochemical and electron microscopic analyses reveal the architecture of the mammalian U2 snRNP.
Krämer A; Grüter P; Gröning K; Kastner B
J Cell Biol; 1999 Jun; 145(7):1355-68. PubMed ID: 10385517
[TBL] [Abstract][Full Text] [Related]
19. SF3b1 mutations associated with myelodysplastic syndromes alter the fidelity of branchsite selection in yeast.
Carrocci TJ; Zoerner DM; Paulson JC; Hoskins AA
Nucleic Acids Res; 2017 May; 45(8):4837-4852. PubMed ID: 28062854
[TBL] [Abstract][Full Text] [Related]
20. Interaction of mammalian splicing factor SF3a with U2 snRNP and relation of its 60-kD subunit to yeast PRP9.
Brosi R; Gröning K; Behrens SE; Lührmann R; Krämer A
Science; 1993 Oct; 262(5130):102-5. PubMed ID: 8211112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
